OLYMPIA-5: A phase 3 trial of odronextamab in people with relapsed or refractory follicular or marginal zone lymphoma

This trial aims to test the medication odronextamab when given with lenalidomide in people with follicular lymphoma (FL) or marginal zone lymphoma (MZL) which has returned after (relapsed) or not responded to (refractory) treatment.  

You can share the following clinicaltrials.gov Identifier with your medical team so they can find out more about the trial: NCT06149286 

Trial aim and background  

The aim of this trial is to assess the effectiveness and safety of the medication odronextamab when given with lenalidomide in patients with relapsed or refractory FL and MZL.  

Participants in this trial will either receive odronextamab and lenalidomide in combination, or the current standard-of-care treatment rituximab in combination with lenalidomide.  

The trial will be in two parts:

  • Part 1: The aim is to see how safe and well tolerated odronextamab is when used with lenalidomide, and to establish a dose.
  • Part 2: The aim is to see how well it works compared to the current standard-of-care treatment regimen.

Who can enter

Adults with FL or MZL which is refractory to, or has relapsed after at least two other treatments may be eligible for this trial.

Locations

Recruitment is taking place at the following UK locations:

  • University Hospitals Plymouth NHS Trust, Plymouth
  • Royal Bournemouth Hospital, Bournemouth

Further information

More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: https://clinicaltrials.gov/study/NCT06149286

Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.